Fig. 3: Anti-SARS-CoV-2 RBD monoclonal antibodies. | Nature

Fig. 3: Anti-SARS-CoV-2 RBD monoclonal antibodies.

From: Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Fig. 3

a, EC50 for SARS-CoV-2 RBD of antibodies isolated at 1.3 (n = 152) 6.2 (n = 153) and 12 (n = 174) months after infection3,4, determined by ELISA. Two-sided Kruskal–Wallis test with subsequent Dunn’s multiple comparisons (1.3 months versus 6.2 months, P = 0.27; 1.3 months versus 12 months, P = 0.0075; 6.2 versus 12 months, P < 0.0001). b, SARS-CoV-2-neutralizing activity of monoclonal antibodies measured using a SARS-CoV-2 pseudovirus neutralization assay3,13. IC50 values for antibodies isolated at 1.3, 6.2 and 12 months after infection against wild-type SARS-CoV-2 (Wuhan-Hu-1 strain41) are shown. Each dot represents one antibody. Pie charts illustrate the fraction of non-neutralizing (IC50 > 1,000 ng ml−1) antibodies (grey slices), inner circle shows the number of antibodies tested per group. Horizontal bars and red numbers indicate geometric mean values. Statistical significance was determined through the two-sided Kruskal–Wallis test with subsequent Dunn’s multiple comparisons.

Back to article page